Connecticut House Bill HB06021

Connecticut 2021 Regular Session

• Introduced: 1/28/21
• Refer: 1/28/21

Caption

An Act Prohibiting The Administration Of Certain Vaccines.

Impact

If enacted, HB 6021 would significantly alter the current vaccination landscape within the state by imposing stringent criteria on which vaccines may be administered. This could lead to a reduction in the number of available vaccines for public use, particularly those not meeting the extensive safety standards outlined in the bill. Critics of the legislation argue that such restrictions may hinder public health initiatives aimed at protecting the community from preventable diseases and outbreaks, potentially endangering public health overall.

Summary

House Bill 6021, introduced by Representative Dauphinais, seeks to amend existing statutes to prohibit the administration of vaccines that do not meet specific criteria set forth by the federal Food and Drug Administration (FDA). The criteria outlined in the bill include the requirement for vaccines to undergo a pivotal trial evaluated against a control group, ensuring that vaccine safety is thoroughly vetted. Additionally, the bill mandates that the vaccine must have been studied for a minimum of one year post-administration to assess any potential long-term health effects, including autoimmune reactions, neurological impacts, and chronic diseases.

Contention

The bill has faced significant debate regarding its implications for public health and vaccination protocols. Proponents assert that this legislation is essential to ensure vaccine safety and transparency, arguing that many vaccines on the market have not undergone rigorous enough testing. Conversely, opponents claim that the bill could foster vaccine hesitancy and ultimately result in decreased immunization rates, which could have dire consequences for overall public health, particularly in vulnerable populations such as children and the elderly.